Dr. Reddy's acquires Betapharm Group for €480 million.
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Dr. Reddy's |
3i |
Acquisition |
Dr. Reddy's will acquire Betapharm Group, a generic pharmaceuticals company, for €480 million. |
|
Nastech |
Galenea |
Acquisition of intellectual property |
Nastech has acquired RNAi intellectual property estate and other RNAi technologies of Galenea for the development of RNAi therapeutics against respiratory viral infections. |
|
Millenia Hope Biopharma |
Avance Pharma |
Purchase |
Millenia Hope Biopharma purchased intellectual property, scientific expertise and the research facilities of the former Avance Pharma. |
|
King Pharmaceuticals |
Arrow International |
Collaborative agreement |
King and Arrow have entered into a collaboration to commercialize novel formulations of Altace. King has rights to certain current and future NDAs, and Arrow got an up-front payment of $35M. |
|
Biosystems International |
AstraZeneca |
Collaborative agreement |
Biosystems International has agreed to collaborate with AstraZeneca on a biomarker discovery program for osteoarthritis. |
|
Par Pharmaceutical |
Spectrum Pharmaceuticals |
Collaborative agreement |
Par Pharmaceutical and Spectrum Pharmaceuticals will develop and market generic drugs, including generic versions of injectable and ophthalmic pharmaceuticals. |
|
Artemis Pharmaceuticals |
Bristol-Myers Squibb |
Collaborative agreement |
Artemis will generate various genetically-engineered murine models carrying selected genetic mutations. BMS will use these models in its drug discovery research activities. |
|
Novavax |
PacificGMP |
Strategic alliance |
PacificGMP will assist Novavax in developing the capability to manufacture large quantities of vaccine to accommodate the surge capacity that must be met in the event of a pandemic outbreak of influenza. |
|
Isis Pharmaceuticals |
Rosetta Genomics |
Development pact |
Isis Pharmaceuticals and Rosetta Genomics will look for new therapies to treat liver cancer and other diseases. |
|
Inspire Pharmaceuticals |
Boehringer Ingelheim |
Development and license deal |
Inspire will acquire certain exclusive rights to develop and market an intranasal dosage form of epinastine in for the treatment or prevention of rhinitis. |
|
Novartis |
Kyorin Pharmaceutical |
Licensing deal |
Novartis has worldwide rights to develop and market Kyorin's immunosuppressant drug KRP-203. Kyorin will receive up-front and milestone payments as well as royalties. |
|
Mitsubishi Pharma, Lequio Pharma |
Yuhan |
Licensing deal |
Yuhan received the exclusive right to import and market ZIONE Injection in Korea. ZIONE was co-developed by Mitsubishi and Lequio. |
|
ImQuest Pharmaceuticals |
Samjin Pharmaceutical |
Licensing deal |
ImQuest Pharmaceuticals has licensed the entire pyrimidinedione series of anti-HIV compounds from Samjin Pharmaceutical. ImQuest plans to develop the lead inhibitor as a therapy for HIV infection. |